Piperazine → HCID 59699580, 화합물

HRID 901230노트

반응식

HRID 901230 반응식
[CH2:1]([O:3][C:4]([C:6]1[C:7](=[O:24])[N:8]([CH2:17][C:18]2[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=2)[C:9]2[C:14]([C:15]=1Cl)=[CH:13][CH:12]=[CH:11][N:10]=2)=[O:5])[CH3:2].[NH:25]1[CH2:30][CH2:29][NH:28][CH2:27][CH2:26]1>ClCCl>[CH2:1]([O:3][C:4]([C:6]1[C:7](=[O:24])[N:8]([CH2:17][C:18]2[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=2)[C:9]2[C:14]([C:15]=1[N:25]1[CH2:30][CH2:29][NH:28][CH2:27][CH2:26]1)=[CH:13][CH:12]=[CH:11][N:10]=2)=[O:5])[CH3:2]

참가 물질

4

반응물 2

HCID 4837PiperazineHCID 59699571HCID 59699571, 화합물

생성물 1

HCID 59699580HCID 59699580, 화합물수율 82%

시약·촉매·용매 1

HCID 6344Dichloromethane용매2회

실험 절차

A solution of 1-benzyl-4-chloro-2-oxo-1,2-dihydro-[1,8]-naphthyridine-3-carboxylic acid ethyl ester (4) (1.2 g, 3.5 mmol) in dichloromethane was added slowly to a stirred solution of piperazine (0.9 g, 10.5 mmol) in dichloromethane at room temperature. The solution was stirred overnight at room temperature. The solvent was evaporated and the residue was suspended in water, sonicated briefly, and extracted with dichloromethane. The combined organic phase was subsequently washed by water and brine, dried over Na2SO4, and evaporated to yield 1.12 g (82%) of 1-benzyl-2-oxo-4-piperazin-1-yl-1,2-dihydro-[1,8]-naphthyridine-3-carboxylic acid ethyl ester (5) as yellow solids. MP: 120° C.; 1H-NMR (DMSO-d6): δ 1.30 (t, J=6.9 Hz, 3H), 2.28 (m, 4H), 3.03 (m, 4H), 4.28 (q, J=6.9 Hz, 2H), 5.55 (s, 2H), 7.16-7.28 (m, 5H), 7.36 (m, 1H), 8.25 (dd, J=1.5, 7.5 Hz, 1H), 8.63 (dd, J=1.5, 7.5 Hz, 1H); EIMS: 393 (M+1), 415 (M+23).

후처리

  1. customThe solvent was evaporated
  2. customsonicated briefly
  3. extractionextracted with dichloromethane
  4. washThe combined organic phase was subsequently washed by water and brine
  5. dry with materialdried over Na2SO4
  6. customevaporated

출처 및 근거

ORD 기록
ord-09c42ebc155c417f845f664aece50f6d
출처 데이터셋
uspto-grants-2008_04
특허 번호
US07361760B2

반응 노트

불러오는 중…